Peptide News Digest

#Tolerance-Bio

2 stories

Industry · View digest

Barclays' Head of US Biopharma Equity Research Emily Field Told CNBC Monday August 24, 2026 That the Biotech Mergers and Acquisitions (M&A) Freeze Is Over, With Capital Markets Reopening, Large-Cap Pharma Buyers Committing to More Deals, and Fresh Oncology Data Extending the Sector's Value Proposition Beyond Weight-Loss Drugs; The Commentary Follows a Rapid Acceleration of Biotech M&A Activity Through August Including Samsung Biologics' Pending $1.8 Billion PolyPeptide Group Acquisition, BioMarin's Alesta Therapeutics Acquisition, Tolerance Bio's $260 Million NT-I7 License From NeoImmuneTech, LEO Pharma's Dersimelagon Acquisition From Mitsubishi Tanabe, and Hanmi Pharm's $2.3 Billion HM17321 Licensing to Genentech Announced the Same Monday

Barclays' Head of US Biopharma Equity Research Emily Field told CNBC Monday August 24, 2026 that the biotech mergers and acquisitions (M&A) freeze is over. Key drivers cited: capital markets reopening (drug startup IPOs have raised roughly $6 billion year-to-date, more than the combined total of the prior four years by this point), large-cap pharma buyers committing to more deals following a multi-year period of caution, and fresh oncology data extending the sector's value proposition beyond the weight-loss drug narrative that dominated 2024-2025. The commentary follows a rapid acceleration of biotech M&A activity through August: Samsung Biologics' pending $1.8 billion PolyPeptide Group AG all-cash tender offer (formal prospectus expected end of August), BioMarin Pharmaceutical's Alesta Therapeutics acquisition for ALE1 program (August 21), Tolerance Bio's $260 million exclusive license from NeoImmuneTech for NT-I7 (efineptakin alfa, long-acting IL-7 fusion protein, August 20), LEO Pharma's dersimelagon (MC1R agonist) acquisition from Mitsubishi Tanabe (August 18), and Hanmi Pharm's up-to-$2.3 billion HM17321 UCN2 licensing to Genentech announced the same Monday. The pattern suggests the M&A environment is now supportive for both mid-cap platform buyers (Samsung Biologics, LEO Pharma, BioMarin) and mega-cap oncology and metabolic-disease buyers (Roche/Genentech, Bristol Myers Squibb, Merck, Eli Lilly) actively pursuing deals. Field's commentary also notes that oncology data (particularly the Merck-Moderna intismeran Phase 3 melanoma win and Gilead Trodelvy+Keytruda EU authorization from the same week) has substantially reset investor expectations about the sector beyond obesity.

Industry · View digest

Tolerance Bio Announced an Exclusive $260 Million License Agreement With South Korean Biotech NeoImmuneTech for the Development and Commercialization of Efineptakin Alfa (NT-I7), a Clinical-Stage Long-Acting IL-7 (Interleukin-7) Fusion Protein, for Certain Thymus-Related Indications in the Americas and Europe; Tolerance Bio Plans to Initiate Phase 2 Clinical Trials Evaluating Efineptakin Alfa for the Enhancement of Thymic Function, With HIV Immunological Non-Response (a Condition Where Patients on Effective Antiretroviral Therapy Fail to Rebuild CD4+ T Cell Counts and a Model of Accelerated Immune Aging) Expected to Be Among the Initial Indications Evaluated; The Agreement Marks Tolerance Bio's Transition to a Clinical-Stage Biotechnology Company, Advancing Efineptakin Alfa in New Indications Aligned With Its Strategy to Preserve Thymic T Cell Output and Enhance Immune Resilience in Immunologically Vulnerable Populations

Tolerance Bio announced an exclusive $260 million license agreement with South Korean biotech NeoImmuneTech for the development and commercialization of efineptakin alfa (NT-I7), a clinical-stage long-acting IL-7 (interleukin-7) fusion protein, for certain thymus-related indications in the Americas and Europe. Mechanism: IL-7 is an immune cytokine that supports T cell development in the thymus and maintenance of memory T cell populations in peripheral tissues. Efineptakin alfa combines the IL-7 cytokine with a fusion partner that extends the half-life from IL-7's native short duration (minutes to hours) to a long-acting profile supporting less-frequent dosing. Tolerance Bio plans to initiate Phase 2 clinical trials evaluating efineptakin alfa for the enhancement of thymic function, with HIV immunological non-response as the lead indication. HIV immunological non-response describes patients on effective antiretroviral therapy who fail to rebuild CD4+ T cell counts to normal levels; it represents a model of accelerated immune aging and provides an established regulatory pathway for demonstrating thymic-function benefit. Additional planned indications include age-related immunosenescence and immune reconstitution after stem cell transplantation. The agreement marks Tolerance Bio's transition to a clinical-stage biotechnology company. Efineptakin alfa has previously been studied in oncology combinations with Merck's Keytruda, BMS's Opdivo, and other checkpoint inhibitors under NeoImmuneTech's development; the Tolerance Bio license refocuses the asset on non-oncology thymus-preservation indications where the long-acting IL-7 mechanism produces broader clinical benefit.